Related Experiment Videos

Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in

Si-Jie Chen1,2,3, Shi-Wei Yue1,2,3, Yun-Pu Zhang1,2,3

  • 1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Insights

Post-translational modifications (PTMs) are central to cancer metabolism reprogramming, interpreting signals to control metabolic flux and malignant phenotypes. This review highlights PTMs as key regulators of cancer cell metabolism and therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells exhibit significant metabolic reprogramming for survival and proliferation.
  • The precise mechanisms governing this rapid metabolic adaptation in cancer remain incompletely understood.

Purpose of the Study:

  • To establish post-translational modifications (PTMs) as the central regulatory unit of oncogenic metabolic reprogramming.
  • To systematically review the role of PTMs in governing cancer metabolism and cell fate.
  • To explore the clinical implications of PTMs in cancer therapy.

Main Methods:

  • Systematic review of literature on PTMs and cancer metabolism.
  • Integration of advances in PTM network determinants and crosstalk.
  • Analysis of PTMs' role in metabolic plasticity and tumor microenvironment.

Main Results:

  • PTMs interpret oncogenic signals, control metabolic flux (glucose, lipid, amino acid, nucleotide utilization), and cement malignant phenotypes.
  • PTMs regulate critical cell fate programs like mitochondrial dynamics, autophagy, and ferroptosis.
  • PTMs are master regulators of immunometabolic reprogramming within the tumor microenvironment, influencing immune evasion.

Conclusions:

  • PTMs encode metabolic plasticity and heterogeneity, creating distinct "PTM geographies" within tumors.
  • PTMs represent promising targets for novel cancer biomarkers and therapies, including targeted protein degradation and PTM-targeted vaccines.
  • Targeting PTMs offers a paradigm shift towards rationally targeting tumor-sustaining computational logic.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...